Investing.comCodex · 实盘不做把握 4/10
北京时间·🕒 发布 08-03 19:12:36时区推断·⟳ 抓取 08-03 19:13:23·⚡ 决策 08-04 09:18:41 +14h05m·84.4 天前
TG Therapeutics 二季度收入 2.403 亿美元并上调 2026 年收入目标
公司二季度全球收入 2.403 亿美元，Briumvi 美国净产品收入 2.277 亿美元同比增长 64%，全年全球收入目标上调至约 9.50 亿美元。
📄 原文Investing.com↗ 原文
TG Therapeutics raises 2026 revenue guidance on Briumvi sales
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks NEW YORK - TG Therapeutics, Inc. (NASDAQ:TGTX)…
不做 TG Therapeutics（TGTX.US）
同一财报/上调收入指引催化已在 08-04 00:52 UTC 处理；当前无新增事实，且市场已对费用上升和利润下降作负向重定价。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 high · price-in 风险 high ↗
消息传播链
- 报道 TG Therapeutics 二季度收入和 Briumvi 销售增长，并上调全年收入目标。市场反应:TGTX.US 最新价 46.195 美元，较前收 -10.94%。
- 2026-08-04 00:52 UTC其它search_processed_events非一手已处理库命中同一财报催化：TGTX 二季度收入超预期并上调全年目标，同时 EPS/利润承压。
关键理由
- 公司二季度全球收入 2.403 亿美元，Briumvi 美国净产品收入 2.277 亿美元同比增长 64%，全年全球收入目标上调至约 9.50 亿美元。
- 但二季度净利润从去年同期 2820 万美元降至 780 万美元，研发和销售费用大幅上升，市场当日下跌 10.94%。
主要风险
- 同一财报与指引催化已在 08-04 00:52 UTC 被处理为不做；正负信息混合且市场已经交易。
工具调用 · 历史记录,结果未知(4 种)
- stock_quote · 结果未知
- search_processed_events · 结果未知
- kb_search · 结果未知
- search_case_library · 结果未知
原文全文
展开原文 · 2,301 字
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks
NEW YORK - TG Therapeutics, Inc. (NASDAQ:TGTX) reported second quarter 2026 total global revenue of $240.3 million and raised its full year revenue guidance, according to a press release statement issued today.
The company reported Briumvi U.S. net product revenue of $227.7 million for the second quarter, representing a 64% increase compared to the same period last year. Total product revenue for the quarter was $235.8 million, compared to $138.8 million in the second quarter of 2025.
Based on the quarterly results, TG Therapeutics raised its full year 2026 total global revenue target to approximately $950 million and increased its Briumvi U.S. net product revenue target to approximately $890 million to $905 million. The company maintained its full year operating expense target of approximately $350 million to $400 million, excluding non-cash compensation, plus approximately $100 million for subcutaneous Briumvi manufacturing and secondary manufacturer costs.
The company reported net income of $7.8 million for the second quarter 2026, compared to net income of $28.2 million in the same period last year. Research and development expenses increased to $95.3 million from $31.8 million year-over-year, primarily due to $54.6 million in subcutaneous manufacturing and secondary manufacturer expenses. Selling, general and administrative expenses rose to $82.1 million from $55.6 million, driven by increased marketing spend and personnel costs.
TG Therapeutics announced positive topline results from its Phase 3 ENHANCE trial evaluating a consolidated single infusion regimen for Briumvi initiation. The trial met its primary endpoint, demonstrating bioequivalent drug exposure between the current two-dose regimen and a single 600 mg infusion.
The company also reported positive Phase 1 data for subcutaneous Briumvi, which demonstrated mean bioavailability greater than 60% relative to intravenous administration. Topline Phase 3 data for the subcutaneous formulation is expected year-end 2026 or early 2027.
Cash, cash equivalents and investment securities totaled $612.3 million as of June 30, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW YORK - TG Therapeutics, Inc. (NASDAQ:TGTX) reported second quarter 2026 total global revenue of $240.3 million and raised its full year revenue guidance, according to a press release statement issued today.
The company reported Briumvi U.S. net product revenue of $227.7 million for the second quarter, representing a 64% increase compared to the same period last year. Total product revenue for the quarter was $235.8 million, compared to $138.8 million in the second quarter of 2025.
Based on the quarterly results, TG Therapeutics raised its full year 2026 total global revenue target to approximately $950 million and increased its Briumvi U.S. net product revenue target to approximately $890 million to $905 million. The company maintained its full year operating expense target of approximately $350 million to $400 million, excluding non-cash compensation, plus approximately $100 million for subcutaneous Briumvi manufacturing and secondary manufacturer costs.
The company reported net income of $7.8 million for the second quarter 2026, compared to net income of $28.2 million in the same period last year. Research and development expenses increased to $95.3 million from $31.8 million year-over-year, primarily due to $54.6 million in subcutaneous manufacturing and secondary manufacturer expenses. Selling, general and administrative expenses rose to $82.1 million from $55.6 million, driven by increased marketing spend and personnel costs.
TG Therapeutics announced positive topline results from its Phase 3 ENHANCE trial evaluating a consolidated single infusion regimen for Briumvi initiation. The trial met its primary endpoint, demonstrating bioequivalent drug exposure between the current two-dose regimen and a single 600 mg infusion.
The company also reported positive Phase 1 data for subcutaneous Briumvi, which demonstrated mean bioavailability greater than 60% relative to intravenous administration. Topline Phase 3 data for the subcutaneous formulation is expected year-end 2026 or early 2027.
Cash, cash equivalents and investment securities totaled $612.3 million as of June 30, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。